German Liver Cancer Study Group

The German Liver Cancer Study Group is an initiative carried out in 2022 by investigators specialized in liver cancer from Frankfurt, Hannover, Mainz and Munich and who are leaders of study groups on hepato-biliary tumors together with the Institute for Clinical Cancer Research IKF in Frankfurt. The German Liver Cancer Study Group is in contact with multinational and intercontinental clinical trials.

• Vision: Improving therapy outcomes for patients with liver tumors, including hepatocellular (HCC) and biliary tract (BTC) cancers, advancing cancer research and helping to provide answers to current and future important clinical questions in this area.
• Mission: Implementation of proof-of-concept studies, therapy optimization studies, translational biomarker research, precision oncology studies, evaluation of the health-related quality of life, and patient-reported outcomes in the field of hepato-biliary malignancies.
• Boards and Members The German Liver Cancer Study Group consist of eight founding members. The members from the four centers are already internationally recognized clinical trial leaders and/or have expertise relevant to achieving the study group's goals.